The therapeutic area of pulmonary vascular and interstitial lung diseases is committed to researching, developing, and offering innovative solutions capable of changing the course of low-prevalence, often potentially life-threatening diseases that affect the small blood vessels of the lungs and the interstitial space located between them and the pulmonary alveoli.
These diseases are characterized by a wide range of symptoms, mainly shortness of breath (dyspnea), with or without physical activity, cough, and chronic fatigue, which may lead to respiratory failure and ultimately death. They significantly limit patients’ quality of life and have a profound emotional and social impact not only on them but also on their caregivers.
The diagnosis and treatment of these diseases continue to pose a challenge for healthcare professionals, making it urgent to deepen research in order to address this gap.
